New drug combo aims to tackle tough lymphoma cases
NCT ID NCT07197307
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 35 times
Summary
This study tests whether combining two drugs, loncastuximab tesirine and epcoritamab, can safely and effectively treat people with aggressive B-cell lymphoma that has come back or not responded to prior therapy. The trial will include 120 adults who have either not had CAR-T cell therapy or whose lymphoma progressed after CAR-T cells. The main goal is to see how many patients achieve a complete or partial remission within 12 months of starting treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Münster, Medizinische Klinik A
Münster, 48149, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.